Skip to main content
Figure 4 | BMC Cancer

Figure 4

From: 3'-Ethynylcytidine, an RNA polymerase inhibitor, combined with cisplatin exhibits a potent synergistic growth-inhibitory effect via Vaults dysfunction

Figure 4

ECyd decreases the expression of vRNAs, a functionally important component of Vaults. A) The expression of MVP protein in KB/CDDP(T) cells treated with 7.0 μmol/L (IC50 value) of CDDP with or without 0.02 μmol/L ECyd (IC50 value) for 24 hours was analyzed using an immunoblot analysis. Equal loading was documented by the detection of β-actin. B) vRNAs expression levels in KB/CDDP(T) cells treated with 0.02 μmol/L (IC50 value) of ECyd were analyzed using a modified qPCR analysis. The columns are the mean ± SD; **P < 0.01, ***P < 0.001 (n = 3). C) vRNAs expression levels in xenograft tumors were analyzed using a modified qPCR analysis. The columns are the mean ± SD; ***P < 0.001 (n = 6).

Back to article page